Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial

Wei Tang, Zhujun Cao, Mingfeng Han, Zhengyan Wang, Junwen Chen, Wenjin Sun, Yaojie Wu, Wei Xiao, Shengyong Liu, Erzhen Chen, Wei Chen, Xiongbiao Wang, Jiuyong Yang, Jun Lin, Qingxia Zhao, Youqin Yan, Zhibin Xie, Dan Li, Yaofeng Yang, Leshan Liu, Jieming Qu, Guang Ning, Guochao Shi, Qing Xie
doi: https://doi.org/10.1101/2020.04.10.20060558
Wei Tang
1Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Roles: chest physician; associate professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhujun Cao
3Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Roles: infectious diseases physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingfeng Han
4Department of Respiratory Medicine. No.2 people’s hospital of Fuyang city, Fuyang, Anhui, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhengyan Wang
5Department of Respiratory Medicine, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junwen Chen
6Department of Respiratory and Critical Care Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, Hubei, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenjin Sun
7Department of Infectious Diseases, Central Hospital of Ezhou, Ezhou, Hubei, China
Roles: infectious diseases physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaojie Wu
8Department of Cardiovascular Medicine, Yunmeng people’s hospital, Xiaogan, Hubei, China
Roles: cardiovascular physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Xiao
9Department of Respiratory Medicine, The First People’s Hospital of Jingzhou City, Jingzhou, Hubei, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shengyong Liu
10Department of Infectious Diseases, Xiaogan hospital affiliated to Wuhan university of science and technology, Xiaogan, Hubei, China
Roles: infectious diseases physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erzhen Chen
11Department of Emergency Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Roles: professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Chen
1Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiongbiao Wang
12Department of Respiratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiuyong Yang
13Department of Respiratory Medicine, Hubei Space Hospital of Xiaogan, Xiaogan, Hubei, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Lin
14Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Roles: gastrointestinal physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingxia Zhao
15Department of Infectious Disease, The Sixth People’s Hospital of Zhengzhou, Zhengzhou, Henan, China
Roles: infectious diseases physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youqin Yan
16Department of Infectious Disease, Wuhan No.7 Hospital, Wuhan, Hubei, China
Roles: infectious diseases physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhibin Xie
17Departments of Respiratory Medicine, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Li
18Department of Respiratory Medicine, The Third People’s Hospital of Yichang, Yichang, Hubei, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaofeng Yang
19Department of Respiratory Medicine, Xiao Gan First People’s Hospital, Xiaogan, Hubei province, China
Roles: chest physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leshan Liu
20Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Roles: associate research fellow (in statistics)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jieming Qu
1Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Roles: chest physician; professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guang Ning
21Shanghai National Research Centre for Endocrine and Metabolic Diseases, State Key Laboratory of Medical Genomics, Shanghai Institute for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Roles: endocrinology physician; professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guochao Shi
1Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Roles: chest physician; professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qing Xie
3Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Roles: professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xieqingrjh{at}163.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives To assess the efficacy and safety of hydroxychloroquine (HCQ) plus standard–of–care (SOC) compared with SOC alone in adult patients with COVID–19.

Design Multicenter, open–label, randomized controlled trial.

Setting 16 government–designated COVID–19 treatment centers in China through 11 to 29 in February 2020.

Participants 150 patients hospitalized with laboratory confirmed COVID–19 were included in the intention to treat analysis. 75 patients were assigned to HCQ plus SOC and 75 to SOC alone.

Interventions HCQ was administrated with a loading dose of 1, 200 mg daily for three days followed by a maintained dose of 800 mg daily for the remaining days (total treatment duration: 2 or 3 weeks for mild/moderate or severe patients, respectively).

Main outcome measures The primary outcome was whether participants had a negative conversion of SARS–CoV–2 by 28 days, and was analyzed according to the intention–to–treat principle. Adverse events were analyzed in the safety population in which HCQ recipients were participants who actually received at least one dose of HCQ and HCQ non–recipients were those actually managed with SOC alone.

Results Among 150 patients, 148 were with mild to moderate disease and 2 were with severe disease. The mean days (± standard deviation, min to max) from symptoms onset to randomization was 16.6 (±10.5 days, 3 to 41 days). The negative conversion probability by 28 days in SOC plus HCQ group was 85.4% (95% confidence interval (CI) 73.8% to 93.8%), similar to that in the SOC group 81.3% (95%CI 71.2% to 89.6%). Between–group difference was 4.1% (95%CI –10.3% to 18.5%). In the safety population, adverse events were recorded in 7 (8.8%) HCQ non–recipients (N=80) and in 21 (30%) HCQ recipients (N=70). The most common adverse event in the HCQ recipients was diarrhea, reported in 7 (10%) patients. Two HCQ recipients reported serious adverse events.

Conclusions The administration of HCQ did not result in a significantly higher negative conversion probability than SOC alone in patients mainly hospitalized with persistent mild to moderate COVID–19. Adverse events were higher in HCQ recipients than in HCQ non–recipients.

Trial registration ChiCTR2000029868

What is already known on this topic

  • — The pandemic of coronavirus disease 2019 (COVID–19) imposes substantial burdens on individuals, communities, health–care facilities, markets, governments, etc. globally.

  • — There is no specific treatment approved for COVID–19 or vaccine to prevent infection with the novel coronavirus.

  • — During the urgent pandemic, media headlines the utility of drugs without solid evidence but buries the side–effects of these drugs.

What this study adds

  • — In this randomized clinical trial of patients mainly with persistent mild to moderate COVID–19, exposure to hydroxychloroquine led to a similar probability of virus elimination comparing to the current standard–of–care.

  • — Adverse events, mostly gastrointestinal related, were significantly increased in patients who received hydroxychloroquine.

  • — Overall, the results from our trial do not support the use of hydroxychloroquine in patients with persistent mild to moderate COVID–19.

Study question To assess the efficacy and safety of hydroxychloroquine (HCQ) plus standard–of–care (SOC) compared with SOC alone in adult patients with COVID–19.

Methods This is a multicenter, open–label, randomized controlled trial conducted in 16 government–designated COVID–19 treatment centers in China through 11 to 29 in February 2020. A total of 150 patients hospitalized with laboratory confirmed COVID–19 were included in the intention to treat analysis. Among them, 75 patients were assigned to HCQ plus SOC and 75 to SOC alone. HCQ was administrated with a loading dose of 1, 200 mg daily for three days followed by a maintained dose of 800 mg daily for the remaining days (total treatment duration: 2 or 3 weeks for mild/moderate or severe patients, respectively). The primary outcome was whether participants had a negative conversion of SARS–CoV–2 by 28 days, and was analyzed according to the intention to treat principle. Adverse events were analyzed in the safety population in which HCQ recipients were participants who actually received at least one dose of HCQ and HCQ non–recipients were those actually managed with SOC alone.

Study answer and limitations Among 150 patients, 148 were with mild to moderate disease and 2 were with severe disease. The mean days (± standard deviation, min to max) from symptoms onset to randomization was 16.6 (±10.5 days, 3 to 41 days). The negative conversion probability by 28 days in SOC plus HCQ group was 85.4% (95% confidence interval (CI) 73.8% to 93.8%), similar to that in the SOC group 81.3% (95%CI 71.2% to 89.6%). Between–group difference was 4.1% (95%CI –10.3% to 18.5%). In the safety population, adverse events were recorded in 7 (8.8%) HCQ non–recipients (N=80) and in 21 (30%) HCQ recipients (N=70) with two serious adverse events. The most common adverse event in the HCQ recipients was diarrhea, reported in 7 (10%) patients. Two HCQ recipients reported serious adverse events.

What this study adds Our trial does not support the use of hydroxychloroquine in patients with persistent mild to moderate COVID–19 due to limited effects on virus eliminating and significantly increased adverse events.

Funding, competing interests, data sharing This work was supported by the Emergent Projects of National Science and Technology (2020YFC0844500), National Natural Science Foundation of China (81970020, 81770025), National Key Research and Development Program of China (2016YFC0901104), Shanghai Municipal Key Clinical Specialty (shslczdzk02202, shslczdzk01103), National Innovative Research Team of High–level Local Universities in Shanghai, Shanghai Key Discipline for Respiratory Diseases (2017ZZ02014), National Major Scientific and Technological Special Project for Significant New Drugs Development (2017ZX09304007), Key Projects in the National Science and Technology Pillar Program during the Thirteenth Five–year Plan Period (2018ZX09206005–004, 2017ZX10202202–005–004, 2017ZX10203201–008). All authors declared no competing interests. Anonymized datasets can be made available on reasonable request after approval from the trial management committee.

Study registration ChiCTR2000029868

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2000029868

Funding Statement

This work was supported by the Emergent Projects of National Science and Technology (2020YFC0844500), National Natural Science Foundation of China (81970020, 81770025), National Key Research and Development Program of China (2016YFC0901104), Shanghai Municipal Key Clinical Specialty (shslczdzk02202, shslczdzk01103), National Innovative Research Team of High-level Local Universities in Shanghai, Shanghai Key Discipline for Respiratory Diseases (2017ZZ02014), National Major Scientific and Technological Special Project for Significant New Drugs Development (2017ZX09304007), Key Projects in the National Science and Technology Pillar Program during the Thirteenth Five-year Plan Period (2018ZX09206005-004, 2017ZX10202202-005-004, 2017ZX10203201-008). The funders played no role in study design, data collection, data analysis, data interpretation, or reporting. The guarantors had full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, and had final responsibility for the decision to submit for publication.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Anonymized datasets can be made available on reasonable request after approval from the trial management committee and after signing a data access agreement. Proposals should be directed to the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted May 07, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial
Wei Tang, Zhujun Cao, Mingfeng Han, Zhengyan Wang, Junwen Chen, Wenjin Sun, Yaojie Wu, Wei Xiao, Shengyong Liu, Erzhen Chen, Wei Chen, Xiongbiao Wang, Jiuyong Yang, Jun Lin, Qingxia Zhao, Youqin Yan, Zhibin Xie, Dan Li, Yaofeng Yang, Leshan Liu, Jieming Qu, Guang Ning, Guochao Shi, Qing Xie
medRxiv 2020.04.10.20060558; doi: https://doi.org/10.1101/2020.04.10.20060558
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial
Wei Tang, Zhujun Cao, Mingfeng Han, Zhengyan Wang, Junwen Chen, Wenjin Sun, Yaojie Wu, Wei Xiao, Shengyong Liu, Erzhen Chen, Wei Chen, Xiongbiao Wang, Jiuyong Yang, Jun Lin, Qingxia Zhao, Youqin Yan, Zhibin Xie, Dan Li, Yaofeng Yang, Leshan Liu, Jieming Qu, Guang Ning, Guochao Shi, Qing Xie
medRxiv 2020.04.10.20060558; doi: https://doi.org/10.1101/2020.04.10.20060558

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)